Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Polycythemia Vera 2Thrombosis 1Thrombocytosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hodgkin Disease 1Glioma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1Bites and Stings 1Adenocarcinoma Of Esophagus 1

Interventions

Temozolomide 22Bevacizumab 10Radiotherapy 5Magnetic Resonance Spectroscopy 5Irinotecan 5Carmustine 4fluorodopa F 18 3Topotecan 3Surgical Procedures, Operative 3Standard of Care 3Radiosurgery 3Magnetic Resonance Imaging 3Congresses as Topic 3Carboplatin 3Aminolevulinic Acid 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3ribociclib 2poly ICLC 2fluoromisonidazole 2carmustine, poliferprosan 20 drug combination 2cabozantinib 2Vorinostat 2TIC10 compound 2Re-Irradiation 2Radiotherapy, Intensity-Modulated 2Panobinostat 2O(6)-benzylguanine 2Melphalan 2Lomustine 2Lacosamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Glioma × Hydroxyurea × Clear all
NCT00290771 2011-05-16

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Novartis

Phase 2 Terminated
231 enrolled 12 charts
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡